n INTRODUCTION J oint involvement is a common manifestation in patients affected by systemic lupus erythematosus (SLE) (1, 2) . The SLE disease activity index 2000 (SLEDAI-2K) is the most frequently used index in the clinical practice for SLE patients (3) . However, the SLEDAI-2K indicates the presence of joint involvement only in case of ≥2 joints with pain and signs of infl ammation, such as tenderness, swelling or effusion (3) . This stringent defi nition may, therefore, fail to identify all the different forms of joint involvement. Kristensen et al. have recently proposed a new index for rheumatoid arthritis (RA) resulting from a ratio of swollen to tender joints based on a 28 joint count named swollen to tender joint count ratio (STR) (4) . This index seems reliable and easy to calculate in the clinical routine, can identify the different degrees of disease activity and does not require the erythrocyte sedimentation rate (ESR) and the patient's assessment, which could be infl uenced by other factors in SLE patients.
N o n -c o m m e r c i a l u s e o n l y
Therefore in this study we aimed to assess joint involvement in a large SLE cohort using the STR clinical marker.
n MATERIALS AND METHODS
During one month, we enrolled 100 consecutive SLE patients with active joint complaints (≥1 tender joint). All patients were referred to the Lupus Clinic, Rheumatology Unit, La Sapienza University of Rome. The study protocol was in compliance with the principle of good clinical practice and the Declaration of Helsinki statements. All patients gave their informed consent to participate in the study. The ethical committee of Sapienza University of Rome approved the study protocol. The diagnosis of SLE was made on the basis of the 1997 American College of Rheumatology (ACR) revised criteria (5) . Clinical and laboratory data, as well as demographics and past medical history with date of diagnosis, comorbidities and previous and concomitant treatments were reported in a standardized electronic form. All patients underwent a complete assessment, including a global health assessment by a visual analogue scale (GH; 0-100 mm). Peripheral blood samples were collected from all patients to evaluate the autoantibody profile and complement serum levels. Specifically, anti-dsDNA antibodies were assessed by indirect immunoflorescence on Crithidia Luciliae in accordance with the manufacturer's instructions (Orgentec Diagnostika, Mainz, Germany). Serum levels of complement C3 and C4 (mg/dL) were examined by radial immunodiffusion. ESR was determined with standard methods (mm/h, Westergren). Disease activity was assessed by using the SLEDAI-2K at the time of the visit (3).
Joint assessment
We initially calculated the STR, which is a ratio based on the count of 28 swollen and tender joints. According to the STR values, SLE patients were grouped into three categories of disease activity: low (STR <0.5), moderate (≤ 0.5 STR ≤1.0), high (STR >1.0) (4). The disease activity score (28-joint count, four variables, ESRbased; DAS28) was calculated. According to DAS28 values, joint disease activity was defined as low (DAS28 ≤3.2), moderate (<3.2 DAS28 ≤5.1) or high (DAS28 >5.1) (6). In the end, the remission status coincided with a DAS28 <2.6 (7).
Statistical analysis
The software packages we used were MedCalc 16.0 (MedCalc Software, Mariakerke, Belgium) and Statistical Package for Social Sciences (SPSS 13.0, Chicago, IL, USA). Data were reported as means and standard deviations (SD) or medians Figure  2A) . The remaining 66 patients without joint involvement defined by SLEDAI-2K had a low STR in 91% of cases and a moderate STR in 9% of cases ( Figure 2B ).
n DISCUSSION AND CONCLUSIONS
In this study, the STR clinical marker was used for the first time to evaluate joint involvement in SLE patients. Our results demonstrate a significant correlation between the STR and DAS28, suggesting the possibility to use it as an easier and faster index. Moreover, STR seems to be more sensitive than SLEDAI-2K in capturing joint involvement. SLE is a systemic autoimmune disease characterized by a multi-factorial etiology, a broad autoantibody profile and het- erogeneous clinical features (8) (9) (10) (11) . The therapeutic strategy in SLE patients should include the control of disease activity and the prevention of chronic damage (12, 13) . Joint involvement can affect up to 90% of SLE patients (1, 2). It is associated with different degrees of severity ranging from mild arthralgia to erosive disease (2) . Data from the literature suggest a prevalent polyarticular involvement and inflammatory signs even in asymptomatic joints (14, 15) . Moreover, the assessment of disease activity and treatment response is crucial in the management of SLE patients with prevalent joint involvement. Several global indexes have been proposed and validated to assess disease activity in SLE patients. The revised SLEDAI-2K is the most frequently used in the clinical practice as well as in observational studies, due to its simplicity and feasibility (3). Among the SLEDAI items, joint involvement is defined as the presence of at least 2 joints with pain and signs of inflammation (i.e., tenderness, swelling or effusion), with a corresponding score of 4 (3). This value is not random in that it highlights the importance of joint involvement, because the disease is considered to be active with a SLEDAI-2K value ≥4. Nonetheless, it is also clear that the definition in the SLEDAI-2K cannot capture all the potential features of joint involvement in SLE patients and cannot therefore reflect fully the evolution of joint involvement during the follow-up. We found a surprisingly high number (9%) of patients without joint involvement according to SLEDAI-2K, who, however, scored a moderate STR. Therefore, also in the light of some results from previous studies (4), this small yet significant sub-population could potentially start a treatment for joint involvement, despite this symptom is not included in the SLE-DAI-2K. Moreover, the degrees of activity identified by the STR seem to be associated with different disease manifestations.
In particular, patients with a high STR showed more frequently neuropsychiatric and renal involvement compared to those with moderate and low activity. Also the positivity for anti-dsDNA and anti-SSA antibodies was significantly more frequent in SLE with high STR-disease activity. It should be considered that the median STR score is low in this cohort and the majority of patients showed a low activity score, indicating a greater number of tender joints compared with swollen ones. We cannot exclude a possible role of a concomitant fibromyalgia, which was not assessed in this analysis.
In conclusion, our study suggests the possibility of using the STR in the assessment of 
